Search
Search Results
-
On the origin and development of glioblastoma: multifaceted role of perivascular mesenchymal stromal cells
Glioblastoma, IDH wild-type is the most common and aggressive form of glial tumors. The exact mechanisms of glioblastoma oncogenesis, including the...
-
MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value
Treatment with the alkylating agent temozolomide is known to be prognostically beneficial in a subset of glioblastoma patients. Response to such...
-
Updates in IDH-Wildtype Glioblastoma
Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021 WHO CNS5 classification has further stressed the importance...
-
Pharmacological Modulation of the Cytosolic Oscillator Affects Glioblastoma Cell Biology
The circadian system is a conserved time-kee** machinery that regulates a wide range of processes such as sleep/wake, feeding/fasting, and...
-
Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy
Epithelioid glioblastoma is a rare aggressive variant of glioblastoma (GBM) characterized by a dismal prognosis of about 6 months and frequent...
-
Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastoma
Glioblastoma is the most frequent and aggressive primary brain tumor, characterized by extensive brain invasion and rarely, systemic metastases. The...
-
Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival
Pleomorphic xanthoastrocytoma (PXA) in its classic manifestation exhibits distinct morphological features and is assigned to CNS WHO grade 2 or grade...
-
The therapeutic potential of Aurora kinases targeting in glioblastoma: from preclinical research to translational oncology
AbstractGlioblastoma is the most common aggressive primary brain tumor. Standard care includes maximal safe surgical resection, radiation, and...
-
Viral vector: potential therapeutic for glioblastoma multiforme
Glioblastoma multiforme is a highly malignant primary brain tumour found in adults and is highlighted as the most devastating among all the other...
-
Insights in the immunobiology of glioblastoma
AbstractGlioblastoma, a grade IV astrocytoma, is considered as the most malignant intracranial tumor, characterized by poor prognosis and therapy...
-
-
Glioma targeted therapy: insight into future of molecular approaches
Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically, gliomas occur among all ages, more often seen in adults,...
-
Clinical and genetic characteristics of carriers of the TP53 c.541C > T, p.Arg181Cys pathogenic variant causing hereditary cancer in patients of Arab-Muslim descent
TP53 pathogenic variants cause Li-Fraumeni syndrome (LFS), with some variants causing an attenuated phenotype. Herein, we describe the clinical...
-
Exosome-based strategies for diagnosis and therapy of glioma cancer
Glioblastoma belongs to the most aggressive type of cancer with a low survival rate that is characterized by the ability in forming a highly...
-
Histone Chaperones in Cancer
Histone epigenetics has three layers including histone modifications, histone variants, and histone chaperones. Unlike the first two components,...
-
Histone Chaperones in Cancer
Histone epigenetics has three layers including histone modifications, histone variants, and histone chaperones. Unlike the first two components,...
-
Glioma: molecular signature and crossroads with tumor microenvironment
In patients with glioblastoma, the average survival time with current treatments is short, mainly due to recurrences and resistance to therapy. This...
-
Major Features of the 2021 WHO Classification of CNS Tumors
Advances in the understanding of the molecular biology of central nervous system (CNS) tumors prompted a new World Health Organization (WHO)...
-
LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study
BackgroundLymphocyte-activation gene 3 (LAG3) is an immune checkpoint receptor; novel LAG3 immune checkpoint inhibitors (ICIs) exhibit therapeutic...
-
Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients
IntroductionNeurotrophic tyrosine receptor kinase ( NTRK ) gene fusions occur in ~ 0.3% of all solid tumours but are enriched in some rare tumour...
